our products & services

The wisdom of the
immune system at work

Adaptive is writing the future of immune-driven medicine through our internal research and in partnership with the larger healthcare community. With products and services, both current and pipeline, supporting life sciences research, clinical diagnostics, and drug discovery, our aim is to add an entirely new dimension to the diagnosis and treatment of disease – from cancer to autoimmune conditions to infectious diseases – in ways that improve people’s lives.

 Life Sciences Research

Pioneering new methods

Using our immunoSEQ Assays, we and our partners can profile individual and collective adaptive immune repertoires by sequencing T- and B-cell receptors. This empowers researchers at hundreds of academic centers and pharmaceutical companies around the world to enhance their study of disease and their drug development efforts. immunoSEQ is also the core of our immune medicine platform. We also launched immunoSEQ T-MAP COVID with the tools to study and analyze the COVID-19 T-cell immune response map.

 Clinical Diagnostics

A new dimension of precision healthcare

We are developing immune-driven clinical diagnostics that may improve the ways in which patients are diagnosed with or monitored for disease.

Our first proprietary diagnostic test, clonoSEQ, is used by clinicians for the detection and monitoring of minimal residual disease (MRD) in bone marrow samples from multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) patients. It is also used by our pharmaceutical partners to monitor response to innovative cancer treatments in clinical trials, and it is the first-ever diagnostic assay powered by immunosequencing to be cleared by the FDA.


Screening TCRs and BCRs for immune-driven therapeutics

Adaptive has developed high-throughput T-cell receptor (TCR) and B-cell receptor (BCR) screening processes that allow for the discovery of antigen-specific TCRs and neutralizing antibodies for use in the development of therapeutics. We are currently leveraging these capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines.